雷宁-血管酶系统抑制剂对骨折风险的影响:全国性嵌套病例控制研究
Kwang Min Kim1, Eun Jung Hwang2, Sangjin Lee3
1Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
BMC musculoskeletal disorders
|January 3, 2024
概括
氨酶系统抑制剂 (RASi) 在老年患者中显著降低骨折风险. 具体来说,血管激素受体抑制剂 (ARBs) 显示出对骨折的保护作用.
科学领域:
- 老年学是指老年学的学科.
- 药理学 药理学是指药理学的学科.
- 整形外科 整形外科 整形外科
背景情况:
- 在骨中局部氨酸-血管酶系统 (RAS) 的激活有助于骨质细胞的再吸收和骨质疏松症.
- 患有骨折风险的老年高血压患者可能受益于RAS抑制剂 (RASi).
研究的目的:
- 调查RASi使用与大型队列中新发育骨折的发生率之间的关联.
- 探索不同RASi类 (ACEi,ARBs) 对骨折风险的具体影响.
主要方法:
- 嵌套病例控制研究设计.
- 1,049例 (新诊断的骨折) 和匹配的对照 (1:1的倾向性得分匹配).
- 条件后勤回归分析以评估RASi暴露和骨折发生率.
主要成果:
- 总体而言,RASi的使用与骨折发生率的几率明显降低相关 (OR,0.73;95% CI,0.59-0.91).
- 仅使用 ангиотензин受体阻断剂 (ARB) 的用户比从未使用过的用户骨折较少 (OR,0.65;95% CI,0.49-0.86).
- 在没有脑血管疾病的RASi使用者中,BMI> 23,以及与他类药物暴露的患者中,观察到骨折风险降低.
结论:
- 使用RASi显著与老年人骨折发生率降低有关.
- 在高危老年人群中,RASi可能成为骨质疏松性骨折的有价值的预防策略.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
735
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
735
01:33Hormonal Regulation
33.2K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
01:11Renal Failure: Dose Adjustments
94
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
94